EX1001 - U.S. Patent No. 12,030,959 to Owen et al. (July 9, 2024) (“US959”) | May 26, 2026 | EXHIBIT | PETITIONER |
EX1004 - Excerpts of prosecution history of U.S. Application 18/486,053 | May 26, 2026 | EXHIBIT | PETITIONER |
EX1005 - NCT03881696, Omalizumab, Version 26 | May 26, 2026 | EXHIBIT | PETITIONER |
EX1006 - Stefanie Arasi et al., Omalizumab as monotherapy for food allergy | May 26, 2026 | EXHIBIT | PETITIONER |
EX1007 - XOLAIR® Prescribing Information, FOOD AND DRUG ADMIN. (Jul. 2021). | May 26, 2026 | EXHIBIT | PETITIONER |
EX1008 - Andrew J. MacGinnitie et al., Omalizumab (2016) | May 26, 2026 | EXHIBIT | PETITIONER |
EX1009 - Phillipe Bégin et al., Phase 1 results of safety (2014) | May 26, 2026 | EXHIBIT | PETITIONER |
EX1010 - Abstract for Maurizio Mennini et al. (2017) | May 26, 2026 | EXHIBIT | PETITIONER |
EX1011 - FDA Grants Breakthrough Therapy Designation for Xolair (2018) | May 26, 2026 | EXHIBIT | PETITIONER |
EX1012 - Breakthrough Therapy, FOOD AND DRUG ADMINISTRATION (Jan. 4, 2018) | May 26, 2026 | EXHIBIT | PETITIONER |
EX1013 - Birth to 24 months (2009). | May 26, 2026 | EXHIBIT | PETITIONER |
EX1014 - 2 to 20 years | May 26, 2026 | EXHIBIT | PETITIONER |
EX1015 - Birth to 24 months | May 26, 2026 | EXHIBIT | PETITIONER |
EX1016 - 2 to 20 years | May 26, 2026 | EXHIBIT | PETITIONER |
EX1017 - Wanda Phipatanakul (2021) | May 26, 2026 | EXHIBIT | PETITIONER |
EX1018 - Judit Crespo (2021) | May 26, 2026 | EXHIBIT | PETITIONER |
EX1019 - XOLAIR® Prescribing Information, FOOD AND DRUG ADMIN. (Mar. 2014) | May 26, 2026 | EXHIBIT | PETITIONER |
EX1020 - Abstract for Stefanie Arasi (2019). | May 26, 2026 | EXHIBIT | PETITIONER |
EX1021 - Clinical trial NIH-PR (2019) | May 26, 2026 | EXHIBIT | PETITIONER |
EX1022 - Sandra Andorf et al., Anti-IgE Treatment (Andorf 2018) | May 26, 2026 | EXHIBIT | PETITIONER |
EX1023 - Asif Rafi et al. (2010) | May 26, 2026 | EXHIBIT | PETITIONER |
EX1024 - Pena Peloche (2011). | May 26, 2026 | EXHIBIT | PETITIONER |
EX1025 - Abstract for Pena Peloche (2011) | May 26, 2026 | EXHIBIT | PETITIONER |
EX1026 - Robert A. Wood et al., Protocol design and synopsis (Nov. 2022) | May 26, 2026 | EXHIBIT | PETITIONER |
EX1027 - Rui Zhu et al., Pharmacokinetics (2021) | May 26, 2026 | EXHIBIT | PETITIONER |
EX1028 - Crisoforo Incorvaia et al, Current and future applications (2008) | May 26, 2026 | EXHIBIT | PETITIONER |
EX1029 - Alessandro Fiocchi (2019) | May 26, 2026 | EXHIBIT | PETITIONER |
EX1030 - Alessandro Fiocchi et al., The use of biologics in food (2021) | May 26, 2026 | EXHIBIT | PETITIONER |
EX1031 - Hugh A. Sampson (2011) | May 26, 2026 | EXHIBIT | PETITIONER |
EX1032 - Jessica H. Savage et al., Kinetics of mast cell, basophil (2012) | May 26, 2026 | EXHIBIT | PETITIONER |
EX1033 - PROTOCOL CoFAR-11, Omalizumab as Monotherapy (2024) | May 26, 2026 | EXHIBIT | PETITIONER |
EX1035 - Francesca Mori (Sept. 2021) | May 26, 2026 | EXHIBIT | PETITIONER |
EX1036 - Caroline Nilsson et al. (2014(("Nilsson") | May 26, 2026 | EXHIBIT | PETITIONER |
EX1037 - Sara Manti (2021) ("Manti") | May 26, 2026 | EXHIBIT | PETITIONER |
EX1038 - Matthias Volmar Kopp, Omalizumab (2011)("Kopp") | May 26, 2026 | EXHIBIT | PETITIONER |
EX1039 - Masaya Takahashi, (Dec. 12, 2017) ("Takahashi") | May 26, 2026 | EXHIBIT | PETITIONER |
EX1040 - C. Martorell-Calatayud, (May 6, 2016) (“Martorell-Calatayud”) | May 26, 2026 | EXHIBIT | PETITIONER |
EX1041 - (March/April 2022) (“Saab”) | May 26, 2026 | EXHIBIT | PETITIONER |
EX1042 - (Dec. 2018) (“Gupta”) | May 26, 2026 | EXHIBIT | PETITIONER |
EX1043 - (Jan. 14, 2019) (“Crisafulli”) | May 26, 2026 | EXHIBIT | PETITIONER |
EX1044 - (Dec. 21, 2016) (“Navinés-Ferrer”) | May 26, 2026 | EXHIBIT | PETITIONER |
EX1045 - (2019) (“Humbert”) | May 26, 2026 | EXHIBIT | PETITIONER |
EX1046 - (May 5, 2009) (“Sandström”) | May 26, 2026 | EXHIBIT | PETITIONER |
EX1047 - (Jan. 2019) (“Nishima”) | May 26, 2026 | EXHIBIT | PETITIONER |
EX1048 - (2019) (“Andorf 2019”) | May 26, 2026 | EXHIBIT | PETITIONER |
EX1049 - (2003) (“Leung”) | May 26, 2026 | EXHIBIT | PETITIONER |
EX1050 - XOLAIR® Omalizumab, FOOD AND DRUG ADMINISTRATION (2003) (“PI2003”) | May 26, 2026 | EXHIBIT | PETITIONER |
EX1051 - XOLAIR® Prescribing Information, FOOD AND DRUG ADMIN. (Jul. 2016) | May 26, 2026 | EXHIBIT | PETITIONER |
EX1052 - (2015) (“Lowe”) | May 26, 2026 | EXHIBIT | PETITIONER |
EX1053 - (“NLM Press Release”) | May 26, 2026 | EXHIBIT | PETITIONER |
EX1003 - Curriculum Vitae of Dr. Asif Rafi | May 26, 2026 | EXHIBIT | PETITIONER |
EX1002 - Declaration of Rafi | May 26, 2026 | EXHIBIT | PETITIONER |
Inter Partes Review Petition of U.S. Patent 12,030,959 | May 26, 2026 | PAPER | PETITIONER |
Petitioner's Power of Attorney Amneal Pharmaceuticals, Inc. | May 26, 2026 | PAPER | PETITIONER |
Petitioner's Power of Attorney Kashiv Biosciences, LLC | May 26, 2026 | PAPER | PETITIONER |